In this closing segment, Dr. Sagar Lonial asks the panel to reflect on the most important unanswered questions that remain in smoldering multiple myeloma research and what evidence is still needed before early treatment strategies are more broadly adopted.
In this segment, Dr. Sagar Lonial asks the panel to discuss real world challenges that may limit the use of early treatment strategies in patients with high risk smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks the panel to discuss how early treatment strategies may influence future therapy options if patients with smoldering multiple myeloma eventually progress to active disease.
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss emerging data evaluating combination treatment strategies in smoldering multiple myeloma. The conversation focuses on studies exploring anti-CD38 antibodies combined with immunomodulatory agents, as well as data involving alternative anti-CD38 therapies such as isatuximab.
In this segment, Dr. Sagar Lonial asks the panel to discuss the potential risks and benefits of early intervention in smoldering multiple myeloma, particularly given that many patients remain asymptomatic for extended periods.
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss the clinical implications of the AQUILA trial, which evaluated daratumumab monotherapy compared with active monitoring in patients with high-risk smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks the panel to reflect on how the treatment landscape has evolved for smoldering multiple myeloma and why early therapeutic intervention is increasingly being discussed for selected high-risk patients.
In this segment, Dr. Sagar Lonial asks Dr. Vincent Rajkumar how clinicians decide between continued observation and early intervention once a patient is classified as having high-risk smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks the panel to comment on emerging data presented at recent ASH meetings examining circulating tumor cells as a potential biomarker in smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss how emerging approaches such as genomic profiling and longitudinal risk assessment may help refine risk stratification in smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss the clinical utility of the IMWG 20/2/20 model in risk stratification for smoldering multiple myeloma.
In this opening segment, Dr. Sagar Lonial welcomes the audience and frames the discussion around the evolving management of smoldering multiple myeloma, before asking the panel how they currently approach risk stratification in clinical practice.
S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.
Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
S. Vincent Rajkumar, MD, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting.
S. Vincent Rajkumar, a professor of Medicine at the Mayo Clinic, Rochester, Minnesota, discusses the prevalence of quadruplet regimens in treating patients with multiple myeloma.
S. Vincent Rajkumar, MD, professor of Medicine at Mayo Clinic, discusses the significance of the phase III SWOG S0777 study, which looked at bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated multiple myeloma.
March 26th 2026
